The POCT market is large and has enjoyed sound growth. From 2008 to 2018, the sales volume of the global POCT market doubled, with an average annual compound growth rate of 7.5%. The global POCT sales volume in 2021 was $31.5 billion.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Nuclein, a leader in rapid, point-of-care molecular diagnostics, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and a Clinical Laboratory Improvement Amendments (CLIA) waiver for its DASH® SARS-CoV-2 & Flu A/B Test for use on the DASH® Rapid PCR System.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher Barrett’s Esophagus test. TissueCypher is the first AI-driven precision medicine test designed to predict a patient’s individual risk of progression from Barrett’s esophagus (BE) to esophageal cancer.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

A transcriptional signature in blood cells called megakaryocytes following vaccination correlates with the strength of an individual's antibody response months later, according to new research.

The U.S. Preventive Services Task Force (USPSTF) recommends four types of screening for cancers: lung cancer, colorectal cancer, breast cancer, and cervical cancer.

OpGen disclosed on Friday that Nasdaq's listing and hearing review council has affirmed an earlier decision by a Nasdaq hearing panel to delist the company's stock.

The Bill & Melinda Gates Foundation awarded more than 500 new grants in the fourth quarter of 2024, many of which are related to diagnostic and omics projects. The following is a selection of notable grants:

Health Canada has granted approval to MedMira’s Multiplo Rapid TP/HIV Test, for HIV and syphilis in Canada.

CDC continues to expect the respiratory disease season will have a similar or lower number of combined peak hospitalizations due to COVID-19, influenza, and RSV compared to last season. This update assesses when peak hospital demand may occur. CDC will update this outlook again in February or as warranted by substantial changes in the spread of any of the three diseases.

Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies.